365Telugu.com online news,April 2, 2025: Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Vancomycin Hydrochloride for Injection USP in three dosage strengths—750 mg/vial, 1.25 g/vial, and 1.5 g/vial (Single-dose vial). This product is bioequivalent and therapeutically equivalent to the reference drug manufactured by Mylan Laboratories Limited under NDA 209481.
JSW MG Motor India Reports 5,500 Unit Sales in March 2025, Achieves 9% YoY Growth
ఇది కూడా చదవండి..తెలంగాణ, ఏపీ రాష్ట్రాల్లో కేర్ హాస్పిటల్స్ ఏఐ ఆధారిత నాన్-ఇన్వేసివ్ చికిత్స ప్రారంభం
According to IQVIA™ sales data for the 12-month period ending January 2025, the market for Vancomycin Hydrochloride for Injection USP in these dosage forms recorded annual sales of approximately $39.3 million.
Expressing enthusiasm about the launch, Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals, stated, “We are pleased to introduce Vancomycin Hydrochloride for Injection USP to our institutional portfolio, reinforcing our commitment to providing high-quality and accessible pharmaceutical solutions.”
Read this also…CARE Hospitals Introduces AI-Powered Non-Invasive Therapy in Telangana & Andhra Pradesh
ఇది కూడా చదవండి..ట్రంప్ టారిఫ్: అమెరికా ప్రతీకార సుంకాలకు శ్రీకారం.. భారతీయ మార్కెట్లపై ప్రభావం..
This launch strengthens Glenmark’s presence in the institutional pharmaceutical sector, reinforcing its focus on delivering quality, effective, and affordable medications to healthcare providers.